Biology Atlas

Map / Modalities

modality · intermediate · partly written

Therapeutic monoclonal antibodies

A therapeutic antibody is a large engineered protein that binds one target outside the cell; the same modality gave a survival gain in breast cancer and a cytokine storm in six volunteers.

Also called: mAb, monoclonal antibody

This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.

The short version

An antibody drug is a large protein, roughly 148 kDa for trastuzumab, that binds the outside of one target. It cannot enter cells, so it works on receptors and signals. Trastuzumab lengthened survival; TGN1412 put six volunteers into cytokine storm. 1234

Reported, not yet replicated

What stays and what changes versus a small molecule more

Still a binder with a target, a dose and a safety question, but the binding surface is large and it acts on the human protein only. That specificity is the strength and the risk: a test species that lacks the target or its cell type gives no warning, as with CD28 in TGN1412. Trastuzumab shows the other side: selecting patients with a companion test makes a single-target antibody effective. 1234

Reported, not yet replicated

Two cases more

Trastuzumab: 469 women, median survival 25.1 versus 20.3 months, heart dysfunction 27 versus 8 percent with an anthracycline. TGN1412: six healthy volunteers, systemic inflammation in 90 minutes, critical illness in 12 to 16 hours, all survived. See both drug records. 23

Reported, not yet replicated

Limits of this record deep

Persistence, clearance and manufacturing were not researched here; no half-life or manufacturing source was opened. 1234

Our inference

What it is

A recombinant monoclonal antibody: a protein of about 148 kDa for trastuzumab, with a binding region for one target and a stem that engages immune cells. 1

Reported, not yet replicated

Intervenes at

Same as small molecule

There is still a molecular target, a dose, an efficacy trial and a safety assessment. Selecting patients on a biomarker is as in targeted small molecules. 1234

Our inference

Changes downstream

Selectivity is for the human protein and cell type, so animal safety testing can mislead. In 2006 the TGN1412 cytokine storm was not predicted, and the regulator group later recommended first doses based on the minimum anticipated biological effect level. 345

Reported, not yet replicated

Delivery

Infused intravenously or injected under the skin; it acts on surface targets from the blood. The subcutaneous trastuzumab product needs hyaluronidase to disperse the dose. 1

Reported, not yet replicated

Persistence

One trastuzumab product is dosed every three weeks, which suggests a long residence; no half-life was read. 1

Our inference

Examples

Teach this

In one sentence

Therapeutic antibodies are large proteins that bind one target outside cells, and whether they help or harm depends on which target and whether the test animal carries it. 1234

Reported, not yet replicated

The five-minute version

An antibody works by binding a surface protein, and trastuzumab, which binds HER2, extended survival in HER2-positive breast cancer but carries a heart warning. TGN1412 bound CD28 on T cells and in 2006 caused a cytokine storm in all six volunteers, because the animals used for safety testing lacked CD28 on the relevant cells. The modality is the same; the target and the species biology differ. 1234

Reported, not yet replicated

What a listener will ask

Can an antibody reach targets inside cells?

The sources opened concern surface receptors; they do not cover intracellular targets.

Is it safer than a small molecule?

Not as a rule: trastuzumab carries a boxed warning and TGN1412 caused severe harm. 1234

Reported, not yet replicated

What is selected on?

Trastuzumab is given on a companion test for HER2. 1234

Reported, not yet replicated

The common wrong idea

Antibodies are so specific that they are safe if animal tests are clean.

Specificity is for the human target and cell type; TGN1412 passed animal tests because the animal cells lacked CD28. 1234

Reported, not yet replicated

The one citation to hand over: 4

Still open here

Linked from

Sources

  1. Genentech, Inc.. Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) prescribing information. FDA Drugs@FDA label, application 761106 (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  2. Slamon DJ, et al.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 (2001). paper; opened 2026-11-17 all records citing this
  3. Suntharalingam G, et al.. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028 (2006). paper; opened 2026-11-17 all records citing this
  4. Eastwood D, Findlay L, Poole S, et al.. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 161:512-526 (2010). paper; opened 2026-11-17 all records citing this
  5. Final ESG report recommends new safeguards for first-in-man trials. PharmaTimes (2006). news, not peer reviewed; opened 2026-11-17 all records citing this
History of this record (5)

This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Status
partly written
Last updated
2026-11-19
Record
content/modalities/antibody.json